Therapy Areas: Central Nervous System
Servier signs strategic collaboration with Nymirum
13 July 2021 -

Servier, a global independent pharmaceutical Group, and Nymirum, a company focused on RNA-targeted small molecules, announced on Monday that they have signed a strategic collaboration to identify and develop RNA-modulatory drugs to treat neurological diseases.

According to the collaboration agreement, Nymirum is to use its proprietary DART Platform (Dynamic Atomic-Resolution RNA Targeting Platform) to discover novel small molecule therapeutics for multiple neurological targets. Servier will be responsible for joint preclinical development and has the right to pursue further development on the present targets and expand its scope. The partnership offers Nymirum with an initial payment, followed by future success payments.

Joshua Fairbank, chief executive officer and co-founder of Nymirum, said, 'We are excited to pair Nymirum's expertise in targeting RNA with Servier's experience in CNS (Central Nervous System) to advance transformative therapies. The ability to resolve and leverage RNA's dynamic structure opens a new chapter for drug discovery, enabling novel programs across all therapeutic areas. Thanks to its expertise in CNS and small molecule therapeutics, Servier is a valuable partner in this collaboration, and together we look forward to accelerating the search for treatments for patients with severe neurological disorders.'

Login
Username:

Password: